Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Recipient : POP Biotechnologies
Deal Size : $1.5 million
Deal Type : Funding
POP BIO and CEPI Announce Collaboration for Faster Responses to Disease X
Details : The funding from CEPI will advance POP BIO’s SNAP (Spontaneous Nanoliposome Antigen Particleization) platform—a plug-and-play technology designed to enable rapid-response vaccine development.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
July 25, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Recipient : POP Biotechnologies
Deal Size : $1.5 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : Gennova Biopharmaceuticals
Deal Size : $13.3 million
Deal Type : Funding
Gennova Expands CEPI Partnership for Nipah Virus saRNA Vaccine Development
Details : The funding aims to advance the clinical development of company's early-stage clinical trial studies for the treatment of Nipah virus infection.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
April 01, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : Gennova Biopharmaceuticals
Deal Size : $13.3 million
Deal Type : Funding
Reset All
